Insider Trading June 29, 2026 04:22 PM

Workday Founder David A. Duffield Executes $12.4 Million Share Sale Under Pre-Arranged Plan

Trust holds over 36.7 million Class B shares; legal and analyst developments continue to shape the cloud HR software landscape.

By Ajmal Hussain
Share
Twitter Reddit Facebook LinkedIn
WDAY

David A. Duffield, a significant ten percent shareholder in Workday, Inc., recently executed a sale of 107,500 shares of the company's Class A Common Stock, generating approximately $12.4 million. The transaction, facilitated through a Rule 10b5-1 trading plan adopted by the David A. Duffield Trust, involved the conversion of an equal number of Class B shares into Class A shares. This move occurs amid a complex backdrop for Workday, which includes ongoing legal challenges regarding its AI-powered HR software and a series of analyst upgrades that highlight divergent market perspectives on the company's valuation and future trajectory.

Workday Founder David A. Duffield Executes $12.4 Million Share Sale Under Pre-Arranged Plan
WDAY
Summarize with
ChatGPT Perplexity Claude Grok Gemini

Key Points

  • David A. Duffield sold 107,500 Class A shares for $12.4 million under a Rule 10b5-1 plan, maintaining a large Class B position.
  • Workday faces federal legal claims regarding potential discrimination in its AI-powered HR software, impacting the enterprise AI sector.
  • Analysts including Monness, Crespi, Hardt, Cantor Fitzgerald, and Oppenheimer have recently upgraded or reaffirmed strong ratings on WDAY despite recent price declines.

David A. Duffield, identified as a ten percent owner of Workday, Inc. (NASDAQ: WDAY), has completed a substantial divestment of company equity. According to a recent filing with the Securities and Exchange Commission, Duffield sold 107,500 shares of Workday's Class A Common Stock. The total value of this transaction reached approximately $12.4 million. The shares were transacted on June 25, 2026, with execution prices ranging between $114.1416 and $118.7611 per share. This sale activity takes place while the stock is currently trading at $123.56, a figure that represents a 9.88% gain over the preceding week, even as the valuation remains down 43% over the past six months. Market analysis from InvestingPro suggests that WDAY may be undervalued at these current levels, placing the stock among those featured on the platform's list of most undervalued companies.

The executed sales were directly preceded by the conversion of 107,500 shares of Class B Common Stock into an equivalent number of Class A Common Stock shares on the identical date. The corporate structure allows Class B shares to be convertible into Class A shares at any time, with automatic conversion triggers also established, as outlined in the company's certificate of incorporation. These specific transactions were carried out in strict adherence to a Rule 10b5-1 trading plan. This pre-arranged framework was initially adopted by the David A. Duffield Trust on December 2, 2025. All shares involved in the reported transactions are held within the David A. Duffield Trust, dated July 14, 1988, for which Mr. Duffield acts as both trustee and sole beneficiary.

Following the completion of these transactions, the trust's direct holdings in Workday consist of 105,049 shares of Class A Common Stock and a substantial position of 36,776,334 shares of Class B Common Stock. This remaining equity structure underscores the continued concentration of ownership within the trust.

Outside of insider trading activity, Workday is navigating several significant operational and market developments. A federal judge has issued a ruling requiring Workday to face legal claims that allege its AI-powered HR software discriminates against job applicants, potentially violating both California and federal laws. This legal scrutiny introduces direct risk to the enterprise software and artificial intelligence sectors, where regulatory compliance regarding automated decision-making tools is increasingly under scrutiny.

Simultaneously, the equity research community has shown divergent but generally constructive views on the stock. Monness, Crespi, Hardt recently upgraded Workday's stock rating to Buy. The firm cited the company's valuation as a primary driver for the upgrade, even while acknowledging a 45% decline in the stock's value during 2026 and a more severe 62% drop since early 2024. This divergence highlights the tension between technical price action and fundamental valuation metrics in the SaaS sector.

Furthermore, Cantor Fitzgerald has reiterated an Overweight rating on Workday shares, maintaining a price target of $160. Oppenheimer also reaffirmed an Outperform rating following a product meeting, setting a price target of $165. These analyst actions suggest that institutional investors are closely monitoring the intersection of Workday's product evolution and its broader market positioning.

Investor sentiment was also reflected at Workday's annual meeting, where stockholders approved director elections and changes to the equity plan. Notable votes were cast in favor of the nominees, indicating shareholder support for the current governance structure. These developments, ranging from legal challenges to analyst upgrades and shareholder approvals, collectively define the current environment for Workday as it operates within the competitive cloud HR software market.

Risks

  • Ongoing federal litigation concerning AI discrimination could result in significant compliance costs and operational constraints for Workday and the broader HR tech sector.
  • The stock has experienced a 45% decline in 2026 and a 62% drop since early 2024, indicating substantial volatility and potential downside risk for equity investors in the SaaS space.
  • Heavy reliance on a single trust for insider ownership concentration may impact market liquidity and perception of insider confidence in the short term.

More from Insider Trading

WidePoint's CEO Executes $2.59M Stock Sale Amid Volatile Run Jun 29, 2026 Sezzle CFO Dickson Offloads $1.68M in Stock Amid Shifting Analyst Sentiment Jun 29, 2026 J.M. Smucker Legal Officer Offloads Shares Amid Strong Earnings and Analyst Optimism Jun 29, 2026 Cg Oncology Director Brian Liu Expands Position with $24.8 Million Share Acquisition Jun 29, 2026 Cytokinetics CFO Executes $266,390 Stock Sale Amidst Myqorzo Launch Momentum Jun 29, 2026